# MDM4

## Overview
MDM4, also known as MDMX, is a gene that encodes the MDM4 protein, a critical regulator of the tumor suppressor protein p53. The MDM4 protein is categorized as a regulatory protein due to its role in modulating p53 activity, primarily through direct binding and inhibition of p53's transcriptional functions. Unlike its homolog MDM2, MDM4 lacks intrinsic E3 ubiquitin ligase activity but enhances MDM2's ability to ubiquitinate and degrade p53 by forming heterodimers. This interaction is essential for maintaining cellular homeostasis and preventing unwarranted cell cycle arrest or apoptosis under normal conditions. MDM4's regulatory functions are modulated by post-translational modifications, such as phosphorylation, which can alter its interaction with p53 in response to cellular stress, such as DNA damage. The gene and its protein product are of significant interest in cancer research due to their involvement in tumorigenesis and potential as therapeutic targets (Liu2024MDM4; Zhang2021Recent; Haupt2019The).

## Structure
MDM4, also known as MDMX, is a protein that plays a crucial role in regulating the tumor suppressor p53. The molecular structure of MDM4 includes several conserved domains: an N-terminal p53-binding domain, a central acidic domain, a zinc finger domain, and a C-terminal RING domain (Perry2009The; Zhang2021Recent). The N-terminal domain is responsible for binding to the p53 protein, specifically interacting with the N-terminal 17-28 residues of p53, which adopt an α-helix conformation (Zhang2021Recent). The RING domain, although lacking intrinsic E3 ligase activity, is important for dimerization with MDM2, influencing MDM2's ubiquitin ligase function (Perry2009The; Egorova2014A).

MDM4 undergoes post-translational modifications, such as phosphorylation, which regulate its interaction with p53. Phosphorylation at specific sites, like Ser367, can lead to p53 activation by promoting MDM4 degradation (Haupt2019The). MDM4 also exists in various isoforms, including MDM4-S and MDM4-FL, which differ in their ability to inhibit p53. MDM4-S is an unstable isoform prone to nonsense-mediated decay, while MDM4-FL is a stable isoform that includes all functional domains (Haupt2019The). These structural features and modifications are critical for MDM4's role in p53 regulation and its implications in cancer.

## Function
The MDM4 gene encodes a protein that plays a crucial role in regulating the tumor suppressor protein p53 in healthy human cells. MDM4 primarily functions by binding to p53 and inhibiting its transcriptional activity, which is essential for maintaining cell viability and preventing unnecessary cell growth restriction (Perry2009The; Haupt2019The). MDM4 achieves this through direct protein-protein interactions, binding to p53's N-terminal transcription activation domain and interacting with its DNA binding domain (Haupt2019The).

MDM4 also works in conjunction with MDM2 to promote p53 degradation by stabilizing MDM2 and enhancing its E3 ligase activity, although MDM4 itself does not possess ubiquitin ligase activity (Perry2009The; Haupt2019The). This regulation is critical during early development, as MDM4 is essential for cell viability and proper embryonic development (Parant2001Rescue).

In response to cellular stress, such as DNA damage, MDM4 is involved in the regulation of p53 activation. Phosphorylation events, such as those mediated by ATM kinase, modulate MDM4's interaction with p53, facilitating p53 synthesis and activation (Perry2009The; Haupt2019The). MDM4's role in these processes is vital for maintaining genomic stability and preventing oncogenic transformation (Haupt2019The).

## Clinical Significance
Mutations and alterations in the MDM4 gene, a key regulator of the p53 tumor suppressor protein, have significant clinical implications in various cancers. MDM4 is often overexpressed in cancers such as lung adenocarcinoma, colon adenocarcinoma, and breast invasive carcinoma, where its elevated expression is associated with poor prognosis and adverse clinical features, including high tumor mutational burden and worse differentiation (Liu2024MDM4). High MDM4 expression is linked to late clinical stages and correlates with poor survival outcomes, making it a prognostic factor for overall survival and disease progression (Liu2024MDM4).

Germline mutations in MDM4, such as the T454M mutation, are associated with conditions like dyskeratosis congenita, characterized by defective telomere maintenance, bone marrow failure, and increased cancer risk. This mutation leads to increased p53 activity, contributing to clinical features such as short telomeres and bone marrow failure (Toufektchan2020Germline). In prostate cancer, high MDM4 expression is observed in metastatic samples and is associated with reduced survival probability, indicating its role in disease progression independent of p53 status (MejíaHernández2022Targeting). MDM4's interactions with oncogenic pathways and its role in creating an immunosuppressive tumor microenvironment further underscore its clinical significance (Liu2024MDM4).

## Interactions
MDM4, also known as MDMX, is a critical regulator of the tumor suppressor protein p53, engaging in several key interactions that modulate p53's activity. MDM4 binds to p53 through its N-terminal domain, which interacts with the N-terminal transcription activation domain of p53, inhibiting its transcriptional activity (Haupt2019The; Zhang2021Recent). This interaction is further stabilized by the zinc finger domain of MDM4, which supports the formation of the MDM2-MDM4 complex (Haupt2019The).

MDM4 also interacts with MDM2, forming heterodimers that enhance the E3 ligase activity of MDM2, leading to increased ubiquitination and degradation of p53 (Zhang2021Recent). The RING domains of MDM4 and MDM2 are essential for their dimerization, which is crucial for their regulatory functions (Zhang2021Recent).

In response to DNA damage, MDM4's interactions are modulated by phosphorylation events. For instance, phosphorylation at Ser289 promotes the engagement of MDM4 with the p53 DNA binding domain, inhibiting p53's transcriptional activity (Haupt2019The; Zhang2021Recent). MDM4 also binds to HIPK2, stabilizing it and facilitating the phosphorylation of p53 at Ser46, which is important for p53's apoptotic functions (Mancini2015MDM4HIPK2p53).


## References


[1. (Parant2001Rescue) John Parant, Arturo Chavez-Reyes, Natalie A. Little, Wen Yan, Valerie Reinke, Aart G. Jochemsen, and Guillermina Lozano. Rescue of embryonic lethality in mdm4-null mice by loss of trp53 suggests a nonoverlapping pathway with mdm2 to regulate p53. Nature Genetics, 29(1):92–95, August 2001. URL: http://dx.doi.org/10.1038/ng714, doi:10.1038/ng714. This article has 391 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng714)

[2. (Zhang2021Recent) Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu, and Yujun Zhao. Recent progress and clinical development of inhibitors that block mdm4/p53 protein–protein interactions. Journal of Medicinal Chemistry, 64(15):10621–10640, July 2021. URL: http://dx.doi.org/10.1021/acs.jmedchem.1c00940, doi:10.1021/acs.jmedchem.1c00940. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.1c00940)

[3. (Egorova2014A) Olga Egorova and Yi Sheng. A site-directed mutagenesis study of the mdmx ring domain. Biochemical and Biophysical Research Communications, 447(4):696–701, May 2014. URL: http://dx.doi.org/10.1016/j.bbrc.2014.04.065, doi:10.1016/j.bbrc.2014.04.065. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2014.04.065)

[4. (Toufektchan2020Germline) Eléonore Toufektchan, Vincent Lejour, Romane Durand, Neelam Giri, Irena Draskovic, Boris Bardot, Pierre Laplante, Sara Jaber, Blanche P. Alter, José-Arturo Londono-Vallejo, Sharon A. Savage, and Franck Toledo. Germline mutation of mdm4 , a major p53 regulator, in a familial syndrome of defective telomere maintenance. Science Advances, April 2020. URL: http://dx.doi.org/10.1126/sciadv.aay3511, doi:10.1126/sciadv.aay3511. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciadv.aay3511)

[5. (Perry2009The) M. E. Perry. The regulation of the p53-mediated stress response by mdm2 and mdm4. Cold Spring Harbor Perspectives in Biology, 2(1):a000968–a000968, November 2009. URL: http://dx.doi.org/10.1101/cshperspect.a000968, doi:10.1101/cshperspect.a000968. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a000968)

[6. (Liu2024MDM4) Jie Liu, Jie Yang, Qilong Pan, Xiangyu Wang, Xinyin Wang, Han Chen, Xiaoling Zheng, and Qingling Huang. Mdm4 was associated with poor prognosis and tumor-immune infiltration of cancers. European Journal of Medical Research, January 2024. URL: http://dx.doi.org/10.1186/s40001-024-01684-z, doi:10.1186/s40001-024-01684-z. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40001-024-01684-z)

[7. (Mancini2015MDM4HIPK2p53) F Mancini, L Pieroni, V Monteleone, R Lucà, L Fici, E Luca, A Urbani, S Xiong, S Soddu, R Masetti, G Lozano, A Pontecorvi, and F Moretti. Mdm4/hipk2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early dna damage response. Oncogene, 35(2):228–240, May 2015. URL: http://dx.doi.org/10.1038/onc.2015.76, doi:10.1038/onc.2015.76. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2015.76)

[8. (MejíaHernández2022Targeting) Javier Octavio Mejía-Hernández, Dinesh Raghu, Franco Caramia, Nicholas Clemons, Kenji Fujihara, Thomas Riseborough, Amina Teunisse, Aart G. Jochemsen, Lars Abrahmsén, Giovanni Blandino, Andrea Russo, Cristina Gamell, Stephen B. Fox, Catherine Mitchell, Elena A. Takano, David Byrne, Panimaya Jeffreena Miranda, Reem Saleh, Heather Thorne, Shahneen Sandhu, Scott G. Williams, Simon P. Keam, Ygal Haupt, and Sue Haupt. Targeting mdm4 as a novel therapeutic approach in prostate cancer independent of p53 status. Cancers, 14(16):3947, August 2022. URL: http://dx.doi.org/10.3390/cancers14163947, doi:10.3390/cancers14163947. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14163947)

[9. (Haupt2019The) Sue Haupt, Javier Octavio Mejía-Hernández, Reshma Vijayakumaran, Simon P Keam, and Ygal Haupt. The long and the short of it: the mdm4 tail so far. Journal of Molecular Cell Biology, 11(3):231–244, March 2019. URL: http://dx.doi.org/10.1093/jmcb/mjz007, doi:10.1093/jmcb/mjz007. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/jmcb/mjz007)